

# Assessment of effectiveness of nonspecific antidiarrheal agents in reducing the need for intravenous rehydration in children with acute diarrhea

S. Bhuvaneshwari T. Shanmugham<sup>1</sup>, Suresh V. Dange<sup>2</sup>, Madhukant H. Nandagavli<sup>3</sup>, Madhav M. Mutalik<sup>4</sup>,

<sup>1</sup>Dr. S. Bhuvaneshwari T. Shanmugham, MBBS, DCH, Ph.D (Med. Pharmacology), Assistant Professor, Department of Pharmacology, Andaman & Nicobar Islands Institute of Medical Sciences (ANIIMS), Port Blair, India, <sup>2</sup>Dr. Suresh V. Dange, MBBS, MD, DNB, Professor, Department of Pharmacology, D.Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil University, Pimpri, Pune, Maharashtra, India, <sup>3</sup>Dr. Madhukant H. Nandagavli, MBBS, MD, Consultant Pathologist, Medifriend Path Lab, Chakan, Pune, Maharashtra, India, <sup>4</sup>Dr. Madhav M. Mutalik, MBBS, MD, Associate Professor, Department of Pharmacology, MIMER Medical College, Talegaon (D), Pune, Maharashtra, India.

**Address for Correspondence:** Dr. S. Bhuvaneshwari T. Shanmugham, **Email Id-** nmadhukant7@gmail.com

## Abstract

**Background:** In clinical practice, nonspecific antidiarrheals are most commonly used by clinicians along with routine treatment to hasten the recovery and to give psychological reassurance. This study was conducted to assess the effectiveness of nonspecific antidiarrheal agents in reducing the need for intravenous rehydration in children with acute diarrhea. **Materials and Methods:** This was a prospective, observational study done in clinical settings for a period of 3 years at two pediatric clinics and at a tertiary care hospital. Children were divided into 5 treatment groups (viz, control, racecadotril, Mebarid, Diarex and loperamide) at the discretion of the pediatrician. One questionnaire was provided to parents to record the details about the course of diarrhea. Parents were sensitized to report any episode of complication or need for intravenous fluids. **Results:** The unscheduled need for intravenous fluids due to dehydration was significantly higher in control group compared to other groups {Control: 7.37%, Racecadotril : 1.71% Mebarid: 2.4%, Diarex: 0%, Loperamide : 0%}. **Conclusion:** Present study suggests that use of nonspecific antidiarrheals may decrease the need for admission for intravenous fluids in children with acute diarrhea.

**Key words:** Acute diarrhea, Diarex, Loperamide, Mebarid, Nonspecific antidiarrheals, Racecadotril

## Introduction

Acute diarrhea accounts for significant morbidity and mortality in children [1]. It is also a cause of anxiety and economic burden to parents of affected children as well as the nation. In developing countries it is mostly infectious in origin and is very often self limiting. Acute diarrhea is defined as diarrhea occurring within a minimum period of 24 hours and lasting usually for less than 7 days [1].

Antimicrobial agents have limited role as most episodes of diarrhea are caused by viruses and enterotoxigenic E.coli. Antibiotics do not alter the course of illness [2, 3]. ORS forms the mainstay in treatment of diarrhea [2-

4]. Its use prevents and corrects dehydration, reduces the morbidity and mortality; but it does not reduce frequency & volume of stools or the duration of diarrhea [3].

Therefore, an effective anti-diarrheal treatment to prevent / reduce dehydration by reducing the frequency and duration of diarrhea would be beneficial. Hence, in clinical practice, nonspecific antidiarrheals (allopathic and ayurvedic) are commonly used by clinicians along with routine treatment, to hasten the recovery and to provide psychological relief [5-7]. Although they are used extensively in clinical practice, there are variable opinions and reports regarding their effectiveness [5-9].

Manuscript received: 31<sup>st</sup> Dec 2015  
Reviewed: 09<sup>th</sup> Jan 2016  
Author Corrected: 18<sup>th</sup> Jan 2016  
Accepted for Publication: 27<sup>th</sup> Jan 2016

It is unclear whether use of these drugs leads to reduced need for IV rehydration as very few studies have considered this outcome. Hence, the present study was planned to assess whether the use of non-specific anti-diarrheal agents leads to reduction in the need for intravenous rehydration.

In our pilot study, it was observed that racecadotril, loperamide, Mebarid, and Diarex were the most commonly advised nonspecific anti-diarrheals. Therefore, these agents were included in the study.

Mebarid, a polyherbal preparation contains Bael, Ajmoda, Lodhara, Dadim, Badishep, Daruhlad, Jaiphal, Sunth, Ativis and Kuda. Diarex is a herbomineral ayurvedic preparation containing Kuda, Guduchi, Bael Dadim, Shankh bhasma and Musta.

## Materials and Methods

**Settings:** This was a prospective, observational study done in clinical settings for a period of 3 years. The study protocol was approved by Institutional Ethics Committee of MIMER Medical College, Talegaon, Pune. It was conducted at following centres after obtaining their permission

1. Pediatric clinic (secondary care hospital), Talegaon, Pune, Maharashtra.
2. Pediatric clinic (secondary care hospital), Chakan, Pune, Maharashtra.

**Table 1: Inclusion criteria**

1. Age: 2 - 10 years.
2. Acute diarrhea of varied etiology.
3. Duration of diarrhea of < 2 days.
4. Diarrhea with mild co – morbidity.
5. No h/o of treatment with antimicrobials/anti-diarrheals/antimotility drugs within the preceding 7 days.

**Table 2: Details of treatment received by children during study**

Drug	Dosage forms	Dose	Frequency
ORS (new formula hypoosmolar ORS)	Powder	as per WHO guidelines	as per WHO guidelines
Racecadotril	Tab, sachets	1.5 mg/kg/dose	Thrice daily
Mebarid	Liquid	<5 y 5ml twice daily >5 y 5ml thrice daily	Thrice daily
Diarex	Tab	<5 y 1/2 tab twice daily. >5 y 1 tab twice daily	Thrice daily
Loperamide	Tab	0.25 mg/kg/day 2-5y; Max 3mg/d 6-8 y; Max 4 mg/d 8-10 y; Max 6 mg/day	Thrice daily

3. Tertiary care hospital, Talegaon, Pune, Maharashtra.

The purpose of the study was explained to the concerned pediatricians and concerned authorities.

**Study population and study design:** Children suffering from acute diarrhea and fulfilling the selection criteria (Table 1) were enrolled into the study. Then parents of children were informed about the study in simple and lucid language. Informed written consent was obtained from parents of the children. Assent was obtained from children between 7 to 10 years. Baseline demographic and clinical characteristics were recorded which included- Age, weight, immunization status, history of fever, vomiting, or other symptoms, prior use of any medication, diarrhea duration, frequency, character of stools (watery, mucoid, bloody etc), consistency of stool, dehydration status etc.

Children were divided into 5 treatment groups at the discretion of the pediatrician. All children received oral rehydration therapy (ORT) and one of the nonspecific anti-diarrheal drugs included in the study (Table 2). The anti-diarrheals were prescribed till recovery. Control group consisted of patients who did not receive any nonspecific anti-diarrheal in addition to oral rehydration therapy. Exclusion criteria are shown in table 3.

**Table 3: Exclusion criteria**

1. Age < 2 and > 10 years.
2. Iatrogenic / bloody diarrhea / or severe diarrhea e.g. cholera.
3. Diarrhea with severe dehydration / significant systemic illnesses.
4. Children with severe malnutrition (BW<50% of expected for that age)
5. Children receiving pre / probiotics and / or zinc supplements or any other nonspecific anti-diarrheal drug not

**Data collection and data analysis:** Prescription audit was conducted and prescriptions were analyzed in detail. Administrations of concomitant medications such as antipyretics, antiemetics were recorded. A questionnaire was provided to parents and they were instructed to fill and record the details of the diarrheal episodes till recovery. All the information was recorded in a predesigned CRF (Case Report Form) including the details of treatment drugs, which was filled on enrollment day in detail and on follow up days. Follow up was done on 3<sup>rd</sup>, 5<sup>th</sup> and 7<sup>th</sup> day of treatment. In cases of failure to follow up, personal visit was done by investigator. A telephonic check was carried out daily. Any episode of complication or need for unscheduled use of intravenous fluids was recorded.

**Statistical analysis:** Statistical analysis was done by appropriate methods using SPSS version 17 and primer of biostatistics. Data obtained are expressed as mean  $\pm$  SEM. P<0.05 was considered as significant.

## Results

600 patients were enrolled and out of which 584 successfully completed the study as per the protocol. Sixteen patients did not turn for the follow up; however, telephonic feedback was obtained successfully. Hence the data has been expressed of all 600 patients. Overall compliance in our study was good (90%). The base-line parameters are shown in Table 4. There was no significant difference between two groups.

**Table 4: The base-line parameters of patients in the study**

Parameters	Control (n=190)	Racecadotril (n=175)	Mebarid (n=123)	Diarex (n=78)	Loperamide (n=34)
Age(y)	4.79 $\pm$ 0.16	4.16 $\pm$ 0.14	4.43 $\pm$ 0.20	7.05 $\pm$ 0.19 *	7.65 $\pm$ 0.26 *
Sex (M:F)	103:87	84:91	54:69	40:38	19:15
Weight (Kg)	16.07 $\pm$ 4.24	15.03 $\pm$ 3.62	15.45 $\pm$ 4.47	20.54 $\pm$ 3.32*	21.59 $\pm$ 3.06*
Fully immunized	133 (70)	143 (82)	93 (76)	55 (71)	28 (82)
Partially immunized	57 (30)	32 (18)	30 (24)	23 (29)	6 (18)
No dehydration	102 (54)	78 (45)	69 (56)	31 (40)	20 (59)
Some dehydration	88 (46)	97 (55)	54 (44)	47 (60)	14 (41)
Duration of diarrhea before enrolment (h)	45.16 $\pm$ 1.13	41.55 $\pm$ 1.27	42.24 $\pm$ 1.34	40.61 $\pm$ 1.70	39.84 $\pm$ 2.35
Frequency of stools/day	4.98 $\pm$ 0.12	5.18 $\pm$ 0.14	5.27 $\pm$ 0.17	5.49 $\pm$ 0.21	5.68 $\pm$ 0.30
Vomiting (No.of children)	24 (13)	18 (10)	26 (21)	9 (12)	5 (9)
Fever (No.of children)	35 (18 )	21 (12)	11 (9)	14 (18)	3 (9)
Comedication:					
Antiemetics	12 (50)	8 (44)	19 (73)	6 (67)	5 (100)
Antpyretics	21 (60)	15 (71)	10 (91)	10 (71)	2 (67)
(No.of children)					
Antibiotics for co-morbidity (No.of children)	40 (21)	37 (21)	30 (24)	25 (32)	4 (12)
Values are mean $\pm$ SEM. Figures in parenthesis indicate percentage.					

**Table 5: Distribution of children according to intravenous rehydration in various study groups**

Group	Need for intravenous rehydration	
	Given (%)	Not given (%)
Control	14 (7.37) *	176 (92.63)
Racecadotril	3 (1.71)	172 (98.29)
Mebarid	3 (2.40)	120 (97.60)
Diarex	0	78 (100)
Loperamide	0	34 (100)
Total	20 (3.33)	580 (96.67)

P < 0.005

In all the children given various antidiarrheal drugs, the need for intravenous rehydration was significantly less as compared to those in control group (Table 5).

The unscheduled need for intravenous fluids due to dehydration was significantly higher in control group (7.37%) compared to all other groups treated with non-specific anti-diarrheal agents. In current study, we have compared control group with other groups. No intergroup comparison has been made.

Only 1.71% children needed unscheduled intravenous intervention in racecadotril group compared to 7.37% children in control group; indicating that racecadotril reduced the admissions needed for intravenous rehydration.

## Discussion

In a hospital based study by Manfredi M et al (2013) [10] in children, 26.9% in the racecadotril supplemented group and 42.9% in ORS group needed i.v. rehydration due to dehydration respectively. This was a retrospective study with a small sample size (n=61) conducted in a primary care hospital and included children with mild to moderate dehydration. The reason cited for parenteral therapy in these children was worsening and persistence of symptoms. However in present study, comparatively very few children (1.71%) in racecadotril group needed intravenous rehydration. The difference observed might be because of differences in patient population.

In the present study, no child on loperamide needed unscheduled IV intervention indicating that loperamide was very effective in preventing the need for i.v.rehydration.

Very few children (2.4%) on Mebarid required i.v. intervention compared to control. No patient from Diarex group required hospitalization for i.v. intervention indicating that supplementation of Diarex reduced the need for hospitalization for i.v. rehydration therapy. The decrease in frequency and duration of diarrhea resulting from administration of these non-

specific anti-diarrheal agents might be responsible for the reduced need for intravenous rehydration. This may result in decrease in the cost of treatment and allay the anxiety associated with hospitalization. Very few studies are available in literature on these antidiarrheals assessing this clinically and economically important outcome measure. Further multicentric studies are necessary to assess the efficacy and safety of such agents in large population of patients.

## Conclusions

Present study suggests that use of nonspecific anti-diarrheals leads to decrease in the need for admission for intravenous fluids in children with acute diarrhea. Hence, it may be appropriate to use such drugs in management of acute diarrhea in children.

**Acknowledgements:** Authors are thankful to all participants of study for their participation and pediatricians and nursing personnel for their valuable support. Special thanks to Dr. A. V. Tilak and Dr. Ranjit Wagh for their constant support and guidance. We are thankful to Mr. Borle P for his advise and expert opinion on statistics.

**Funding:** Nil, **Conflict of interest:** None.

**Permission of IRB:** Yes

## References

1. Ravi Shankar, Singh SP, Tripathi CB. Persistent diarrhea: approaches for the management among under-five children. *Indian J. Prev. Soc. Med.* 2004;35(3,4):112-120. Available from: <http://medind.nic.in/ibl/t04/i3/iblt04i3p112g.pdf>.

2. Tripathi KD. *Essentials of medical pharmacology*. 6<sup>th</sup> ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd.; 2008. Chapter 48, Drugs for constipation and diarrhea. p660-64.

3. Ghai OP, Gupta P, Paul VK, editors. *Ghai essential pediatrics*. 6<sup>th</sup> ed. New Delhi: CBS publishers; 2005.

4. WHO Department of Child and Adolescent Health and Development (CAH), MOHFW. *Student's handbook for Integrated management of neonatal and childhood illness*. 2003.

5. Turck D, Berard H, Fretault N, et al. Comparison of racecadotril and loperamide in children with acute diarrhea. *Aliment Pharmacol Ther.* 1999;13(6):27-32.

Doi: 10.1046/j.1365-2036.1999.00004.x-i1.

6. Li S-TT, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children: Systematic review and meta-analysis. *PLOS med.* 2007; 4(3):e98. Doi:10.1371/journal.Pmed.0040098.

7. Hamza H., Khalifa HB., Baumer P, Berard H., Lecomte JM. Racecadotril versus placebo in the treatment of acute diarrhoea in adults. *Aliment. Pharmacol. Ther.* 1999; 13 (6): 15–19. Doi: 10.1046/j.1365-2036.1999.00002.x-i1.

8. Cézard J P, Duhamel J F, Meyer M. Efficacy and tolerability of racecadotril in acute diarrhea in children. *Gastroenterology.* 2001;120(4):799-805. <http://www.cimerman.com.br/artigos/Pediatria/tiorfan%20em%20crian%C3%A7as-%20diarreia%20aguda.pdf>.

9. Santos M, Maranon R, Miguez C, Vazquez P, Sanchez C et al. Use of racecadotril as outpatient treatment for acute gastroenteritis: a prospective, randomized, parallel study. *J pediatr.* 2009;155(1):62-7. Doi:10.1016/j.jpeds.2009.01.064.

10. Manfredi M, Bizzarri B, de'Angelis GL. Racecadotril at the Beginning of Pediatric Gastroenteritis: A Small Experience of a Primary Level Hospital. *Clin Microbiol.* 2013; 2(1): 102. doi:10.4172/2327-5073.1000102.

## How to cite this article?

S. Bhuvaneshwari T. Shanmugham, Suresh V. Dange, Madhukant H. Nandagavli, Madhav M. Mutalik. Assessment of effectiveness of nonspecific antidiarrheal agents in reducing the need for intravenous rehydration in children with acute diarrhea. *Int J Med Res Rev* 2016;4(1):55-59. doi: 10.17511/ijmrr.2016.i01.009.